ibi325
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 14, 2022 (NCT05119998)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- 5'-nucleotidaseANTAGONIST
NT5E antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05246995 | Phase 1 | Mar 23, 2022 | Shandong University |
| NCT05119998 | Phase 1 | Feb 14, 2022 | Innovent Biologics (Suzhou) Co. Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Shandong University | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1